Significantly Greater Expression of ER, PR, and ECAD in Advanced-Stage Low-Grade Ovarian Serous Carcinoma as Revealed by Immunohistochemical Analysis

Wong, Kwong-Kwok; Lu, Karen H.; Malpica, Anaís; Bodurka, Diane C.; Shvartsman, Hyun S.; Schmandt, Rosemarie; Thornton, Angela; Deavers, Michael T.; Silva, Elvio G.; Gershenson, David M.

doi:10.1097/pgp.0b013e31803025cd

Cited by 127 publications

(81 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The expression of ER in ovarian serous carcinomas in our study was not associated with tumor grade or neoadjuvant chemotherapy. In contrast to our observation, higher ER and E-cadherin expression was reported for low-grade ovarian serous carcinomas than for high-grade ovarian serous carcinomas by Wong et al 35 It is possible that we could not detect a significant difference in ER expression between low-and high-grade ovarian serous carcinoma in any of the markers results from limited sample size of low-grade tumors in our study. O'Neill et al 36 found significantly higher expression of p53 and HER2/neu in high-grade ovarian serous carcinoma when compared with low-grade tumors.…”

Section: Discussioncontrasting

confidence: 99%

Immunophenotyping of serous carcinoma of the female genital tract

et al. 2008

View full text Add to dashboard Cite

To update the data on the expression of 'mesothelioma markers' by serous carcinomas of various sites we have studied cases from ovary (n ¼ 56), endometrium (n ¼ 37), fallopian tube (n ¼ 6), primary peritoneum (n ¼ 5) and cervix (n ¼ 3) using a panel of antibodies (WT1, P53, estrogen receptors, HER2/neu, D2-40, cytokeratin 5/6 and E-cadherin). Ovarian carcinomas demonstrated D2-40 and cytokeratin 5/6 immunoreactivity in 23.2 and 55.4% of cases, respectively. Endometrial carcinomas demonstrated D2-40 and cytokeratin 5/6 immunoreactivity in 43.2 and 37.8% of cases, respectively. D2-40 staining pattern was predominantly focal; however, strong reactivity was identified in 16.2% of endometrial and 10.7% of ovarian carcinomas. HER2/neu oncoprotein overexpression was demonstrated in 7 of 37 (18.9%) uterine serous carcinomas. In contrast, all the serous carcinomas of the other sites were HER2/neu negative. The proportion of positive cases was significantly different in ovarian vs endometrial carcinomas regarding WT1 (P ¼ 0.0458), estrogen receptors (Po0.001) reactivity and HER2/neu overexpression (P ¼ 0.0025). D2-40 and cytokeratin 5/6 are expressed in a considerable proportion of serous carcinomas and should be used cautiously in a 'mesothelioma panel' in situations where serous carcinoma is in the differential diagnosis. HER2/neu was exclusively overexpressed in serous carcinomas of endometrial origin.

show abstract

Section: Discussioncontrasting

confidence: 99%

Immunophenotyping of serous carcinoma of the female genital tract

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In a recent study, Wong et al [27] used immunohistochemical analysis to compare the expression of various markers in tumor samples from women with advancedstage low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. These investigators reported that the low-grade tumors expressed signifi cantly higher levels of estrogen receptor, progesterone receptor, and Ecadherin than the high-grade tumors did.…”

Section: Pathologic and Molecular Characteristicsmentioning

confidence: 99%

Low-grade serous ovarian cancer: a unique disease

Schmeler¹,

Gershenson

2008

Curr Oncol Rep

Self Cite

View full text Add to dashboard Cite

“…70% of relapses. 7,10,11 In addition, in both tumor types, women # 35 years of age have worse outcomes compared with older women. 5 On the basis of our clinical experience, LGSC does not seem to be completely resistant to platinum-based chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum

Gershenson

Bodurka

Coleman

et al. 2017

JCO

Self Cite

222

144

View full text Add to dashboard Cite

The purpose of this study was to examine outcomes associated with hormonal maintenance therapy (HMT) compared with routine observation (OBS) after primary cytoreductive surgery and platinum-based chemotherapy in women with stage II to IV low-grade serous carcinoma of the ovary or peritoneum. Patients and MethodsEligibility criteria for patients from our database were: treatment with primary surgery followed by platinumbased chemotherapy, stage II to IV disease, at least 2 years of follow-up for patients who had not experienced recurrence, and adequate clinical information. The two groups were compared for progressionfree survival (PFS) and overall survival, and a multivariable Cox regression analysis was performed. Subset analyses for patients who were disease free or had persistent disease were also performed. ResultsBetween 1981 and 2013, 203 eligible patients-133 who underwent OBS and 70 who received HMT-were seen at our institution. Median PFS for patients who underwent OBS was 26.4 months, compared with 64.9 months for those who received HMT (P , .001). No statistically significant difference in overall survival was observed between the two groups (102.7 v 115.7 months, respectively). For subgroups of women who were disease free or had persistent disease, median PFS was superior for those who received HMT (81.1 v 30.0 months; P , .001 and 38.1 v 15.2 months; P , .001, respectively). Women who received HMT had a significantly lower risk of disease progression compared with those who underwent OBS (hazard ratio, 0.44; 95% CI, 0.31 to 0.64; P , .001). ConclusionWomen with stage II to IV low-grade serous carcinoma who received HMT after primary treatment had significantly longer PFS compared with women who underwent OBS. These findings warrant further investigation using a prospective trial design.

show abstract

Significantly Greater Expression of ER, PR, and ECAD in Advanced-Stage Low-Grade Ovarian Serous Carcinoma as Revealed by Immunohistochemical Analysis

Cited by 127 publications

References 28 publications

Immunophenotyping of serous carcinoma of the female genital tract

Immunophenotyping of serous carcinoma of the female genital tract

Low-grade serous ovarian cancer: a unique disease

Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum

Contact Info

Product

Resources

About